Runben Biotechnology (SH:603193) Wanlian Securities·2025-10-27 10:04Investment Rating - The report adjusts the investment rating to "Accumulate" based on the company's performance and market conditions [4]. Core Views - The company, Runben Co., Ltd. (603193), achieved a revenue of 1.238 billion yuan in the first three quarters of 2025, representing a year-on-year increase of 19.28%, while the net profit attributable to the parent company was 266 million yuan, up 1.98% year-on-year [2][3]. - In Q3 2025, the company experienced a revenue growth of 16.67% year-on-year, but the net profit decreased by 2.89% year-on-year, indicating pressure on profitability [3]. - The gross margin declined slightly to 58.27%, and the net profit margin decreased to 21.50%, primarily due to increased sales and financial expense ratios [3]. - The mosquito repellent product line saw significant revenue growth in Q3 2025, driven by the chikungunya virus outbreak and changes in product structure, with revenues reaching 132 million yuan, a year-on-year increase of 48.54% [4]. Summary by Sections Financial Performance - For the first three quarters of 2025, the company reported a revenue of 1.238 billion yuan and a net profit of 266 million yuan, with a slight decline in the net profit margin [2][3]. - The average selling price of mosquito repellent products increased by 12.04% in Q3 2025, contributing to the revenue growth [4]. Profitability Analysis - The company's gross margin decreased by 0.06 percentage points to 58.27%, and the net profit margin fell by 3.65 percentage points to 21.50% due to rising sales and financial expenses [3]. Future Outlook - The report revises the earnings per share (EPS) forecast for 2025-2027 to 0.80, 0.94, and 1.08 yuan per share, respectively, reflecting adjustments in profit expectations [4]. - The price-to-earnings (PE) ratios for 2025, 2026, and 2027 are projected to be 33, 28, and 24 times, respectively, based on the adjusted EPS [4].